Home › Peripheral Arterial Disease › NCT07613840

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and/or closed revascularization.
* Patients at the age of 18 or older

Exclusion Criteria:

* Patients who are younger than 18 years old
* Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)
* Prisoners, defined as those who have been directly admitted from a correctional facility.
* No atherosclerosis
* Subject has active stomach ulcers
* Subject has severe hepatic impairment
* Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of \>1 year, the study team will consult with the

About the study

The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs.

The main questions it aims to answer are:

* Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure? * Does the personalized plan lower rates of amputation, repeat procedures, bleeding, and death compared to standard treatment?

Researchers will compare the personalized TARGET plan which uses a blood test to tailor each person's blood clot prevention medication to the standard treatment to see if the personalized approach works better.

Participants will:

* Be randomly assigned to either the personalized TARGET plan or standard treatment after their procedure * Have blood tests at 1 week and at 1, 3, 6, 9, and 12 months after their procedure * Have medications adjusted based on blood test results if assigned to the TARGET group

What is being tested

• Aspirin (drug)
• Clopidogrel (drug)
• Ticagrelor (drug)
• Rivaroxaban (drug)
• Thromboelastography with Platelet Mapping (device)

Sponsor: Massachusetts General Hospital · Participants: 484 · Started: Apr 29, 2025

Contact the study team

• Anahita Dua, MBCHB, MBA, MSC · Phone: 262-565-8247
• Swechha Bhatt, MBBS · Phone: 339-242-0052

Official record on ClinicalTrials.gov — NCT07613840

Locations in the U.S.

Conditions

• Peripheral Arterial Disease
• Blood Clots

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.